BCL2 and neoplasm: ROR1 expression was identified in 93% (52/56) of SCLC tumors, while BCL2 expression was identified in 86% (48/56) of SCLC tumors, and 83% (45/56) of SCLC tumors showed expression of both ROR1 and BCL2 in the same tumor cells.